Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 15/20 | 0.57 |
| ▸ | ICAM1 | P05362 | 15/20 | 0.57 |
| ▸ | ITGAL | P20701 | 15/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830219 | 0.91 | ITGB2 (0.59) | ITGB2ICAM1ITGALALPL | |
| SCHEMBL27557327 | 0.79 | HPGD (0.51) | POLBHPGDHTTALDH1A1MAPT | |
| SCHEMBL5830304 | 0.78 | ITGB2 (0.56) | ITGB2ICAM1ITGALALDH1A1MEN1 | |
| SCHEMBL5830523 | 0.78 | ITGB2 (0.65) | ITGB2ICAM1ITGALHPGDMEN1 | |
| SCHEMBL5830926 | 0.76 | ITGB2 (0.61) | ITGB2ICAM1ITGALHPGDALDH1A1 | |
| SCHEMBL5830958 | 0.72 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL5830843 | 0.72 | ALDH1A1 (0.46) | ITGB2ICAM1ITGALPOLBHPGD | |
| SCHEMBL5829927 | 0.72 | ITGB2 (0.68) | ITGB2ICAM1ITGALHPGDMEN1 | |
| SCHEMBL5830251 | 0.72 | ITGB2 (0.68) | ITGB2ICAM1ITGALHTTMEN1 | |
| SCHEMBL6570114 | 0.70 | ITGB2 (0.49) | ITGB2ICAM1ITGALKMT2AALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39197-E1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2006-07-18 | — | — | US | claimed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | claimed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | claimed |
| US-RE39197-E1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | disclosed |
| US-6867203-B2 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1481968-A2 | Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds | Abbott Laboratories (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| US-6110922-A | ARYL SULFIDE CONTAINING PENDANT CIS- OR TRANS-CINNAMIDE GROUPS | ABBOTT LABORATORIES (US) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ICAM1, VCAM1, EPCAM | ITGB2 32/4885ICAM1 1/4885ITGAL 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.